Ignite Creation Date:
2025-12-25 @ 4:10 AM
Ignite Modification Date:
2025-12-26 @ 3:07 AM
Study NCT ID:
NCT02126020
Status:
WITHDRAWN
Last Update Posted:
2017-04-07
First Post:
2014-04-27
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Topical Infliximab in Autoimmune Eyes With Keratoprosthesis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D013262', 'term': 'Stevens-Johnson Syndrome'}, {'id': 'D013577', 'term': 'Syndrome'}, {'id': 'D010390', 'term': 'Pemphigoid, Benign Mucous Membrane'}], 'ancestors': [{'id': 'D013280', 'term': 'Stomatitis'}, {'id': 'D009059', 'term': 'Mouth Diseases'}, {'id': 'D009057', 'term': 'Stomatognathic Diseases'}, {'id': 'D003875', 'term': 'Drug Eruptions'}, {'id': 'D003872', 'term': 'Dermatitis'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D004892', 'term': 'Erythema Multiforme'}, {'id': 'D004890', 'term': 'Erythema'}, {'id': 'D012872', 'term': 'Skin Diseases, Vesiculobullous'}, {'id': 'D006968', 'term': 'Hypersensitivity, Delayed'}, {'id': 'D006967', 'term': 'Hypersensitivity'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D004342', 'term': 'Drug Hypersensitivity'}, {'id': 'D064420', 'term': 'Drug-Related Side Effects and Adverse Reactions'}, {'id': 'D064419', 'term': 'Chemically-Induced Disorders'}, {'id': 'D004194', 'term': 'Disease'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D003229', 'term': 'Conjunctival Diseases'}, {'id': 'D005128', 'term': 'Eye Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069285', 'term': 'Infliximab'}], 'ancestors': [{'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 0}}, 'statusModule': {'whyStopped': 'No patients met eligibility criteria. The study has been closed.', 'overallStatus': 'WITHDRAWN', 'startDateStruct': {'date': '2014-11'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-04', 'completionDateStruct': {'date': '2017-04-03', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-04-05', 'studyFirstSubmitDate': '2014-04-27', 'studyFirstSubmitQcDate': '2014-04-27', 'lastUpdatePostDateStruct': {'date': '2017-04-07', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2014-04-29', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2017-04-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Tolerability', 'timeFrame': '1 year', 'description': 'Percentage of patients finishing 12 months of topical infliximab use'}, {'measure': 'Adverse events', 'timeFrame': '2 years', 'description': 'Number and type of adverse events'}, {'measure': 'rate of corneal melting', 'timeFrame': '2 years', 'description': 'rate of corneal melting or ulceration during infliximab prophylaxis (12 months) and after the drug is stopped (following 12 months)'}, {'measure': 'KPro retention', 'timeFrame': '2 years', 'description': 'Percentage of retained KPros at 2 years'}], 'secondaryOutcomes': [{'measure': 'Visual acuity', 'timeFrame': '2 years'}, {'measure': 'Ocular surface symptoms', 'timeFrame': '2 years', 'description': 'Ocular surface symptoms as assessed by ocular surface disease index score'}, {'measure': 'Ocular surface inflammation', 'timeFrame': '2 years', 'description': 'Ocular surface inflammation using slit-lamp photographs and the ocular redness index (ORI)'}, {'measure': 'tear matrix metalloproteinase (MMP)', 'timeFrame': '2 years', 'description': 'Levels and activity of MMPs, myeloperoxidase and tissue inhibitor of MMP-1'}, {'measure': 'graft thickness', 'timeFrame': '2 years', 'description': 'Corneal carrier graft thickness as measured by anterior segment optical coherence tomography before, during and after treatment with infliximab'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Keratoprosthesis', 'corneal melt', 'keratolysis', 'Tumor necrosis factor alpha', 'infliximab', 'matrix metalloproteinase'], 'conditions': ['Stevens-Johnson Syndrome', 'Toxic Epidermal Necrolysis (Lyell) Syndrome', 'Mucous Membrane Pemphigoid']}, 'descriptionModule': {'briefSummary': "The Boston Keratoprosthesis type I (KPro) is a prosthetic cornea used to treat several causes of corneal blindness. Some categories of patients, including those with auto-immune diseases such as Stevens-Johnson syndrome, toxic epidermal necrolysis syndrome and mucous membrane pemphigoid, have a higher risk of failure for the KPro. Because of chronic inflammation, the cornea supporting the KPro may melt, leading to a higher risk of infection, loss of the KPro and loss of the eye.\n\nInfliximab is an antibody against tumor necrosis factor alpha and is used intravenously to control inflammation in several diseases. It has been used in some cases of corneal melting with significant success.\n\nThis study's hypothesis is that infliximab can be successfully used as an eye drop (instead of the usual administration through veins) and that its regular use may prevent melt in eyes with a Boston Keratoprosthesis type I and underlying auto-immune disease.", 'detailedDescription': 'This is an unmasked, prospective, multicenter clinical trial of four patients that are candidates for a Boston Keratoprosthesis or have had prior KPro surgery and have a diagnosis of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis syndrome (TENS) or mucous membrane pemphigoid (MMP). Only one eye per patient will be considered for inclusion.\n\nThis is a phase I/II study to evaluate the safety and tolerance of topical infliximab 10 mg/mL eye drops. Research subjects will be required to administer infliximab eye drops four times per day for three months followed by twice daily administration for nine months. The subjects will be monitored while on the study medication as well as for one year following discontinuation of the drug. The total study duration for each patient will be two years.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Able to provide informed consent\n* Underlying diagnosis of SJS, TENS, or MMP\n* Implantation of a Boston KPro type I\n* Able to administer eye medications or have a care giver able and willing to do same\n* Negative tuberculosis screening\n\nExclusion Criteria:\n\n* Active or recurrent ocular or systemic infection\n\n * Chest radiography, QuantiFERON-TB Gold or purified protein derivative (PPD) evidence of active or latent tuberculosis infection\n * Indeterminate initial and repeat QuantiFERON-TB Gold results\n * History of Bacille Calmette-Guerin (BCG) vaccination within twelve months of screening\n * History of latent or active granulomatous infection, including histoplasmosis or coccidioidomycosis, prior to screening\n * Chest radiograph within three months prior to the first administration of the study drug that shows an abnormality suggestive of a malignancy or current active infection, including tuberculosis.\n * History of a nontuberculous mycobacterial infection or opportunistic infection (e.g. cytomegalovirus, pneumocystosis, aspergillosis) within six months prior to screening\n * history of hepatitis B virus\n * Methicillin resistant Staphylococcus aureus (MRSA) or vancomycin resistant enterococcus (VRE) infection\n* Malignancy diagnosed in the last five years\n* Demyelinating disease\n* History or current diagnosis of diabetes mellitus (controlled and uncontrolled)\n* Heart failure (New York Heart Association class III or IV)\n* Pregnancy or breast-feeding\n* Scheduled to receive a live vaccine at any time point during study participation\n* Allergy to infliximab or any of the compounds in its topical formulation or any chemically-related medication\n* Prior or current use of systemic anti-tumor necrosis alpha-α medications or currently receiving treatments of Kineret (Anakinra)\n* KPro designs with less than 16 holes in the back plate (to avoid the confounder of corneal nutrition)\n* Inability to comply with the instillation of additional drops\n* Unable to attend postoperative visits or administer medications, or no care giver available and willing to assist with same'}, 'identificationModule': {'nctId': 'NCT02126020', 'briefTitle': 'Topical Infliximab in Autoimmune Eyes With Keratoprosthesis', 'organization': {'class': 'OTHER', 'fullName': 'Massachusetts Eye and Ear Infirmary'}, 'officialTitle': 'Topical Infliximab in Autoimmune Eyes With Keratoprosthesis', 'orgStudyIdInfo': {'id': 'MEEI 13-110H'}, 'secondaryIdInfos': [{'id': 'IND 122719', 'type': 'OTHER', 'domain': 'FDA'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'topical infliximab', 'description': 'topical infliximab 10 mg/mL QID x 3 months followed by BID x 9 months', 'interventionNames': ['Drug: topical infliximab']}], 'interventions': [{'name': 'topical infliximab', 'type': 'DRUG', 'otherNames': ['Remicade'], 'description': 'topical infliximab administered QID for 3 months followed by BID for 9 months', 'armGroupLabels': ['topical infliximab']}]}, 'contactsLocationsModule': {'locations': [{'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Massachusetts Eye and Ear Infirmary', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': 'H2L 4M1', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': "Centre Hospitalier de l'Université de Montréal", 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}], 'overallOfficials': [{'name': 'James Chodosh, MD, MPH', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Massachusetts Eye and Ear Infirmary'}, {'name': 'Claes H Dohlman, MD, PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'Massachusetts Eye and Ear Infirmary'}, {'name': 'Mona Harissi-Dagher, MD', 'role': 'STUDY_CHAIR', 'affiliation': "Centre hospitalier de l'Université de Montréal (CHUM)"}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'James Chodosh, MD, MPH', 'class': 'OTHER'}, 'collaborators': [{'name': 'Massachusetts Eye and Ear Infirmary', 'class': 'OTHER'}, {'name': "Fonds de recherche en ophtalmologie de l'Université de Montréal", 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Associate Director of the Cornea and Refractive Surgery Service, Director of Boston Keratoprosthesis Clinical Programs', 'investigatorFullName': 'James Chodosh, MD, MPH', 'investigatorAffiliation': 'Massachusetts Eye and Ear Infirmary'}}}}